JP2022542803A - （ｒ）－ｎ－（５－（５－イソプロピル－１，２，４－オキサジアゾール－３－イル）－２，３－ジヒドロ－１ｈ－インデン－１－イル）－２－メチル－２ｈ－テトラゾール－５－カルボキサミドの多形 - Google Patents

（ｒ）－ｎ－（５－（５－イソプロピル－１，２，４－オキサジアゾール－３－イル）－２，３－ジヒドロ－１ｈ－インデン－１－イル）－２－メチル－２ｈ－テトラゾール－５－カルボキサミドの多形 Download PDF

Info

Publication number
JP2022542803A
JP2022542803A JP2022502217A JP2022502217A JP2022542803A JP 2022542803 A JP2022542803 A JP 2022542803A JP 2022502217 A JP2022502217 A JP 2022502217A JP 2022502217 A JP2022502217 A JP 2022502217A JP 2022542803 A JP2022542803 A JP 2022542803A
Authority
JP
Japan
Prior art keywords
polymorph
disease
subject
methyl
tetrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502217A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542803A5 (https=
Inventor
ノーマ トム，
デニス アンデルセン，
Original Assignee
サイトキネティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイトキネティックス， インコーポレイテッド filed Critical サイトキネティックス， インコーポレイテッド
Publication of JP2022542803A publication Critical patent/JP2022542803A/ja
Publication of JP2022542803A5 publication Critical patent/JP2022542803A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022502217A 2019-07-17 2020-07-16 （ｒ）－ｎ－（５－（５－イソプロピル－１，２，４－オキサジアゾール－３－イル）－２，３－ジヒドロ－１ｈ－インデン－１－イル）－２－メチル－２ｈ－テトラゾール－５－カルボキサミドの多形 Pending JP2022542803A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875355P 2019-07-17 2019-07-17
US62/875,355 2019-07-17
PCT/US2020/042390 WO2021011809A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide

Publications (2)

Publication Number Publication Date
JP2022542803A true JP2022542803A (ja) 2022-10-07
JP2022542803A5 JP2022542803A5 (https=) 2023-07-25

Family

ID=71995105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502217A Pending JP2022542803A (ja) 2019-07-17 2020-07-16 （ｒ）－ｎ－（５－（５－イソプロピル－１，２，４－オキサジアゾール－３－イル）－２，３－ジヒドロ－１ｈ－インデン－１－イル）－２－メチル－２ｈ－テトラゾール－５－カルボキサミドの多形

Country Status (16)

Country Link
US (1) US20220274969A1 (https=)
EP (1) EP3999181B1 (https=)
JP (1) JP2022542803A (https=)
KR (1) KR20220082803A (https=)
CN (1) CN114667283B (https=)
AU (1) AU2020315433A1 (https=)
BR (1) BR112022000523A2 (https=)
CA (1) CA3144974A1 (https=)
CL (1) CL2022000089A1 (https=)
ES (1) ES2982707T3 (https=)
IL (1) IL289881A (https=)
MX (1) MX2022000498A (https=)
NZ (1) NZ784931A (https=)
PH (1) PH12022550084A1 (https=)
TW (1) TW202116764A (https=)
WO (1) WO2021011809A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2024179422A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515884A (ja) * 2003-01-14 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP7401439B2 (ja) * 2018-01-19 2023-12-19 サイトキネティックス， インコーポレイテッド 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515884A (ja) * 2003-01-14 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP7401439B2 (ja) * 2018-01-19 2023-12-19 サイトキネティックス， インコーポレイテッド 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAM R TAUB ET AL.: "Perturbations in skeletal muscle sarcomere structure in patients with heart failure and Type2 diabet", CLINICAL SCIENCE, vol. 125巻, JPN6023003640, 2013, pages 383 - 389, ISSN: 0005358273 *

Also Published As

Publication number Publication date
US20220274969A1 (en) 2022-09-01
IL289881A (en) 2022-03-01
EP3999181B1 (en) 2024-05-29
CN114667283B (zh) 2023-12-26
CN114667283A (zh) 2022-06-24
KR20220082803A (ko) 2022-06-17
AU2020315433A1 (en) 2022-03-03
NZ784931A (en) 2025-03-28
PH12022550084A1 (en) 2023-04-12
ES2982707T3 (es) 2024-10-17
CA3144974A1 (en) 2021-01-21
EP3999181A1 (en) 2022-05-25
TW202116764A (zh) 2021-05-01
MX2022000498A (es) 2022-02-03
EP3999181C0 (en) 2024-05-29
WO2021011809A1 (en) 2021-01-21
BR112022000523A2 (pt) 2022-03-03
CL2022000089A1 (es) 2022-10-07

Similar Documents

Publication Publication Date Title
CN114555590B (zh) (r)-n-(5-(5-乙基-1,2,4-噁二唑-3-基)-2,3-二氢-1h-茚-1-基)-1-甲基-1h-吡唑-4-甲酰胺的多晶型物
JP2022542803A (ja) （ｒ）－ｎ－（５－（５－イソプロピル－１，２，４－オキサジアゾール－３－イル）－２，３－ジヒドロ－１ｈ－インデン－１－イル）－２－メチル－２ｈ－テトラゾール－５－カルボキサミドの多形
JP7623342B2 (ja) 心臓サルコメア阻害剤の経口用製剤
CN119998292A (zh) 5-(3,4-二氟苄基)-8-((1r,4r)-4-甲基环己基)-6,9-二氧代基-2,5,8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式
RU2846046C2 (ru) Полиморфы (r)-n-(5-(5-этил-1,2,4,-оксадиазол-3-ил)-2,3-дигидро-1н-инден-1-ил)-1-метил-1н-пиразол-4-карбоксамида
HK40121580A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40076616A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40075684A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40111816A (zh) 多晶型物
HK40125944A (zh) 5-(3，4-二氟苄基)-8-((1r，4r)-4-甲基环己基)-6，9-二氧代基-2，5，8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250124